STOCK TITAN

Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the virtual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 8:00 a.m. PT. The company will engage in a fireside chat, accessible via a live and archived webcast on their Investors webpage. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to develop innovative clinical products for disease diagnosis and treatment. The company has three commercial products and a strong clinical pipeline addressing conditions like cancer and autoimmune diseases.

Positive
  • None.
Negative
  • None.

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 14th at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

 


FAQ

When is Adaptive Biotechnologies participating in the Morgan Stanley Global Healthcare Conference?

Adaptive Biotechnologies will participate on September 14, 2021, at 8:00 a.m. Pacific Time.

How can I access the webcast of Adaptive Biotechnologies' conference participation?

The webcast is available live and archived on the Investors section of Adaptive Biotechnologies' website.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies is focused on translating the adaptive immune system's genetics to develop diagnostic and treatment products.

What diseases does Adaptive Biotechnologies target in its clinical pipeline?

The clinical pipeline at Adaptive Biotechnologies targets cancer, autoimmune conditions, and infectious diseases.

What products does Adaptive Biotechnologies currently have?

Adaptive Biotechnologies has three commercial products aimed at diagnosing and monitoring diseases.

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

760.96M
147.47M
1.93%
98.62%
6.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SEATTLE